The ImmunoPrecise Rapid Prime System Reduces the Immunization Stage of Hybridoma Production to 18 Days
04 June 2010 by ImmunoPrecise AntibodiesImmunoPrecise Antibodies is a leading provider of custom monoclonal and polyclonal antibody development. It can deliver some of the fastest turnaround times in the industry.
The ImmunoPrecise Rapid Prime system reduces the immunization stage of hybridoma development to just 18 days, shaving five to eight weeks off the industry standard.
Download this free white paper to find out more.
Available Downloads
-
The ImmunoPrecise Rapid Prime System Reduces the Immunization Stage of Hybridoma Production to 18 Days
Download